CHRYSALIS-2 Trial

[Slide 1] Efficacy Outcomes of First-line Amivantamab + Lazertinib CHRYSALIS-2 Ami Laz in Atypical EGFR+ NSCLC 0 Investigator-assessed response (n=49) NE PD PD SD SD 17.3 mo -20 Median follow-up (range, 0.1-31.5) (95% CI, 42-71) change In SoD of target leclons -40 57% ORR -60 20.7 mo Median DoR (95% CI, 9.9-NE) -80 PR DoR 26 mo, n (%)* 21 (75) N-100 SD 84% ORR CBR Sollary (95% CI, 70-93) 63% Compound 47% 19.5 mo Median PFS EGFR G7TBX (95% Cl, 11.2-NE) 52% EGFR LS61X 67% EGFR STGAX NE 46% Median OS Other (95% Cl, 26.3-NE) 57% The presence of TP53 co-mutation and other pathogenic alterations were not associated with a lower response rate At a median follow-up of 17.3 months, the median PFS was 19.5 months and median OS was NE 4mmg responders CSR 0 defined as the percentage of patients achieving condinmed CR PR or durable SD (duration of 211 weeks) PR CSR partial clinical benefit SO, stable a confidence disease, internal SoD, sum OR of complete diameters response DaR duration of response; EGFR epidemal growth lador receptor, no, months; NE, not eslimable/evaluable: ORR objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; 24 ASCO #ASCO24 PRESENTED un Byoung Chul Cho Copies of this slide deck obtained through Quick Response (QR) UAL MEETING ASCO® AMERICAN SOCIETY OF Presentation a property of the author and ASCO. Permission required for contact permissions@jana.org Code are for personal use only and may not be reproduced without CUNICAL ONCOLOGY permission from ASCO or the authors of these slides. KNOWLEDGE CONQUERS CANCER --- [Slide 2] Efficacy Outcomes of Amivantamab + Lazertinib CHRYSALIS-2 Ami Laz in Among All Patients in Cohort C Atypical EGFR+ NSCLC Investigator-assessed response (n=105) 16.1 mo Median follow-up 40 (range, 0.1-31.5) 52% 20 ORR (95% CI, 42-62) 14.1 mo 0 Median DoR (95% CI, 9.5-26.2) DoR X8 mo, n (%)* 38 (69) % change in BOD of target lesions -20 Best response, n (%) -40 CR 0 PR 55 (52) -60 SD 37 (35) -80 Treatment-naive subgroup PD 8 (8) Previously treated subgroup Not evaluable/UNK -100 5 (5) 79% CBR (95% CI, 70-86) Median PFS 11.1 mo In a heterogeneous population, the median PFS was 11.1 months and median os was NE (95% Cl, 7.8-17.8) NE Median OS (95% CI, 22.8-NE) Anong responders. RSR 0 defined 35 to percentage of patients achieving confirmed CR FR or durable SD (Auration of 211 weeks) CSR oinical will cale, a confidence intenal OR complete response; DOR duration of response; NE, not estimable; OAR, objective response rate: OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; SoD, sum of diameters. ASCO #ASCO24 PRE SENTED or: Byoung Chul Cho Copies of this stide deck obtained through Quick Response (QR) LL MEETING Presentation il property of Do author and ASOO Permission required for rouse, contact permissions@asco erg. Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY permission from ASCO® or the authors of these studes. KNOWLEDGE CONQUERS CANCER

[Slide 1] Comparison of First-Line Therapies for NSCLC with Uncommon EGFR Mutations Therapy Trial Mutations Included N PFS (mo) OS ORR Toxicity Summary Afatinib ACHILLES G719X, L861Q, S7681, 109 10.6 (HR Immatu 61% 44% G3+; diarrhea, rash, compound 0.421) re paronychia Osimertinib UNICORN G719X, L861Q, S7681, 40 9.4 Not 55% 27.5% G3+; ILD (12.5%) compound reached Osimertinib KCSG-LU15- G719X, L861Q, S7681 36 8.2 Not 50% Well tolerated 09 reporte d Amivantamab CHRYSALIS- G719X, L861Q, S7681, ~25 19.5 NA 51% Infusion rxn, rash, + Lazertinib 2 others paronychia @SuyogCancer

[Slide 1] Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2 Presented by: Catherine Shu Abstract #9006 Stage IV NSCLC mutated EGFR ex 19del/L858R Phase 10 Conor day n=162 (Cohort A) dination Amivantamab + Lazertinib - n=50 evaluable Phase the I I PRIMARY OUTCOME: ORR 33% the MEDIAN DOR (MOS) I 9.6 to lines I Chemotherapy 149 Most common grade ≈3 treatment-related AEs (TRAEs) were infusion-related reactions (7%), I 5 acneiform dermatitis (5%). and hypoalbuminemia (4%) I mm VO % Among an unselected population that has exhausted SOC osi and pt-chemo, III III # ami and laz demonstrates encouraging antitumor activity with a - manageable safety profile https://bit.ly/5N9joqC Created by: @ADesaiMD --- [Slide 2] Antitumor Activity of Amivantamab + Lazertinib n/N ORR (95% C) Overall I 54/162 33.3% (26.1%, 41.2%) BICR-assessed Response n=162 Age, years 33/97 34.0% (24.7%, 44.3%) 33% (95% CI, 26-41) <65 ORR >=65 21/65 32.3% (21.2%, 45.1%) Median DOR 9.6 mo (95% Cl, 7.0-NE) Sex Best response, n (%) Male 13/57 22.8% (12.7%, 35.8%) Complete response 2 (1) Female 41/105 39.0% (29.7%, 49.1%) Race Partial response 52 (32) Asian 31/99 31.3% (22.4%, 41.4%) Unconfirmed partial response 1 (0.6) Non-Asian 23/63 36.5% (24.7%, 49.6%) Stable disease 69 (43) Baseline ECOG Performance Status Progressive disease 28 (17) 0 17/49 34.7% (21.7%, 49.6%) >=1 NE 10 (6) 37/113 32.7% (24.2%, 42.2%) History of Smoking Clinical benefit rate 57% (95% CI, 49-65) Yes 14/49 28.6% (16.6%, 43.3%) No investigator-assessed ORR=28% (95% CI, 22-36) 40/111 36.0% (27.1%, 45.7%) Prior line of therapy Investigator-assessed median DOR=8.4 mo (95% CI, 5.6-NE) Osimertinib as 1st Line Median follow-up=10.0 mo (range, 0.3-20.2) Osimertinib as 2nd Line 8/39 20.5% (9.3%, 36.5%) Median progression free survival=5.1 mo (95% CI, 4.2-6.9) Heavily treated or out of sequence 24/67 35.8% (24.5%, 48.5%) Mutation Type 22/56 39.3% (26.5%, 53.2%) Median overall survival=14.8 mo (95% CI, 12.1-NE) Exon 19 del Fecentage BOR Meded of policity with confirmed tesponse a Surable dable disease (duration of 11 Exon 21 LBS8R 36/110 32.7% (24.1%, 42.3%) Ottobogy Group m noths and NE, towards NR evaluatie, a confidence ORR overal interval response DOR duration rate of response, wooks) ECOG, Eastom Cooperative 18/50 36.0% (22.9%, 50.8%) 0 20 40 60 80 100 2022ASCO 33% ASCO22 PAY BY: DMO ANNUAL MEETING Catherine L j Copies Code of for his de deck obtained through Chick Response (QR)

[Slide 1] 6 Best Antitumor Response and ORR by Prior Therapy Group 60 Prior Therapy Groups BICR ORR (95% CI) INV ORR (95% CI) 50 Osimertinib platinum-based chemotherapy (n=39) 21% (9-37) 26% (13-42) 40 1st/2nd-generation EGFR TKI -> osimertinib -> platinum-based chemotherapy (n=67) 36% (25-49) 30% (19-42) 30 Heavily pretreated or out of sequence (n=56) 39% (27-53) 29% (17-42) 20 10 Best Change from Baseline in SoD of Target Lesions (%) 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 10 efficacy-evaluable patients did not have any evaluable post-baseline target lesion measurements BICR, blinded independent central review; CI, confidence interval; EGFR, epidermal growth factor receptor; INV. investigator-assessed; ORR, overall response rate: SoD, sum of diameters; TKI, tyrosine kinase inhibitor. 2022 ASCO PRESENTED BY: Copies of this slide deck obtained through Quick Response (QR) #ASCO22 Code are for personal use only and may not be reproduced Content of this presentation is the property of the ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY Catherine A. Shu without permission from ASCOB or the author of this slides author, licensed by ASCO. Permission required for reuse. ANNUAL MEETING KNOWLEDGE CONQUERS CANCER

[Slide 1] 10 Conclusions Amivantamab + lazertinib demonstrated durable antitumor activity in patients with EGFRm NSCLC. after progressing on both osimertinib and platinum chemotherapy Treatment Activity is comparable to that in previously reported post-osimertinib, chemotherapy-nalve population, suggesting Benefit that intervening chemotherapy does not impact amivantamab + lazertinib activity ⑉ Safety profile of amivantamab + lazertinib is consistent with prior reports; no new safety signals were identified Safety Among a population that has exhausted standard of care including heavily pretreated patients, amivantamab + lazertinib demonstrated clinically significant and durable antitumor activity, without biomarker selection The CHRYSALIS-2 study (ClinicalTrials.gov Identifier: NCT04077463) is ongoing. and the understanding of underlying resistance mechanisms will be reported at a future meeting Key MARIPOSA (NCT04487080) and MARIPOSA-2 (NCT04988295). ongoing phase 3 randomized trials, are evaluating amivantamab * lazertinib in the frontline and amivantamab + lazertinib carboplatin + pemetrexed in Takeaway post-osimertinib settings and Amivantamab monotherapy upcoming in METex14skip oral presentation (ASCO 2022 #9008) Next Steps EGFRm epidermal growth factor receptor-mutated NSOLC non-small cell lung cancer. 1. Baumi al. Presented at ASCO June 4-8 2024 9006 (onal) 2022 ASCO PRESENTION Capien of this deck ICAS #ASC022 Cinde the Contact of dis presentation is the property of the ASCO Catherine A Shu author licensed ity water Permission required for ANNUAL MEETING ENOWLEDGE CONQUERS CANCER --- [Slide 2] 5 Antitumor Activity of Amivantamab + Lazertinib N/M 044 (95% C) Overall BICR-assessed Response n=162 H 14/042 ORR 33% (95% CI, 26-41) - 3399 14.0% Q2.7% you Median DOR 9.6 mo (95% CI, 7.0-NE) I 21/65 45.1% Best response, n (%) Had 1363 22.8% Complete response 2 (1) H 40/305 29.0% (99.7%) 49.1% Partial response 52 (32) *** 31/99 30.3%% (22.4%) m Unconfirmed partial response 1 (0.6) I 23/43 6.3% 24.7% 48.4% Stable disease 69 (43) Performance Status Progressive disease 28 (17) - 1349 M4%217% 49.6% - 13/01/ 2.2% NE 10 (6) Clinical benefit rate 57% (95% CI, 49-65) DANG 43.3% - 40913 Investigator-assessed ORR=28% (95% CI, 22-36) line of therapy Investigator-assessed median DOR=8.4 mo (95% CI, 5.6-NE) Osimertinio an 1st Line 8/39 20.5% (9.3% 36.5% 24/07 35.8% (34.5% 48.5% Median follow-up=10.0 mo (range, 0.3-20.2) 22/54 13.2% Median progression free survival=5.1 mo (95% CI, 4.2-6.9) Multiation Type (not 29 del Median overall survival=14.8 mo (95% .1-NE) wed 16/110 32.7% Q4.1% 42.3% Exam 21 USSIA use 36.0% (22.9% of patients with confirmed response or durabile stable disease (duration if all works) 20 NO 40 so 300 BICR independent central review CI confidence anthonwal DOR duration of response ECOG Convinent Cooperative Oncology Group months NE ALE evaluable ORR overall 33% ASCO - 2022 of the #ASC022 ASCO Catherine A Shu ANNUAL MEETING --- [Slide 3] CHRYSALIS-2 (ClinicalTrails.gov Identifier: NCT04077463) Study Design Dose Expansion Cohorts RP2CD: Lazertinib 240 mg PO + Amivantamab 1050 mg (1400 mg for >80 kg) IV Endpoints Cohort A: EGFR ex19del or L858R Overall response rate (primary) Post-osimertinib and platinum-based chemotherapy (nu 162) Duration of response Cohort B: EGFR 20ins Clinical benefit rate Post-standard of care and platinum-based chemotherapy Progression-free survival Cohort C: Uncommon EGFR mutations Treatment naive or post-1 or 2nd generation EGFR TKI Overall survival Cohort D: EGFR ex19del or L858R Adverse events Post-osimertinib, chemotherapy naive, biomarker validation Here we present updated safety and efficacy results of the amivantamab and lazertinib combination from fully enrolled Cohort A *Percentage of patients with continued response or durable stable disease (duration of 211 weeks) EGFR growth factor receptor; exticie each 19 deletion es20ins. exon 20 insertion; N. intravenous PO per onal RP2CO recommended phase 2 combination dose TO tyrosine kinane inhibitor 2022 ASCO #ASC022 the property ASCO Catherine A Shu was ANNUAL MEETING